Equities

Lifecore Biomedical Inc

Lifecore Biomedical Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)6.74
  • Today's Change0.35 / 5.48%
  • Shares traded227.32k
  • 1 Year change-6.78%
  • Beta0.9517
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy0
Outperform1
Hold2
Sell0
Strong Sell0

Share price forecast in USD

The 2 analysts offering 12 month price targets for Lifecore Biomedical Inc have a median target of 7.00, with a high estimate of 8.00 and a low estimate of 6.00. The median estimate represents a 3.86% increase from the last price of 6.74.
High18.7%8.00
Med3.9%7.00
Low-11.0%6.00

Earnings history & estimates in USD

On Oct 04, 2024, Lifecore Biomedical Inc reported 1st quarter 2025 losses of -0.49 per share.
The next earnings announcement is expected on Aug 07, 2025.
Average growth rate-100.89%
Lifecore Biomedical Inc reported annual 2024 earnings of 0.34 per share on Aug 26, 2024.
Average growth rate-262.26%
More ▼

Revenue history & estimates in USD

Landec Corporation had 1st quarter 2025 revenues of 24.71m. This bettered the 23.19m consensus of the 3 analysts covering the company. This was 34.79% below the prior year's 1st quarter results.
Average growth rate-7.32%
Landec Corporation had revenues for the full year 2024 of 128.26m. This was 24.20% above the prior year's results.
Average growth rate-23.47%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.